Sensex
77,562.90 profit arw 2,946.32 (3.95%)
Nifty
23,997.35 profit arw 873.70 (3.78%)
Nasdaq
18,355.20 profit arw -497.09 (-2.64%)
logo img

GET IN TOUCH

GET IN TOUCH

Refresh Captcha
Equity

As on : 08-Apr-2026
Corporate News
08-Apr-2026     19:18

Lupin receives USFDA approval for Dapagliflozin and Metformin Hydrochloride XR Tablets

Lupin today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, 10 mg/1,000 mg. The company also received tentative approval for Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets, 2.5 mg/1,000 mg.

The U.S. FDA has approved Lupin's Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets as bioequivalent to Xigduo' XR for the indications in the approved labeling.

INDIAN INDICES

Sensex

77,562.90 2,946.32 (3.95%)

Nifty

23,997.35 873.70 (3.78%)

GLOBAL INDICES

USD

NA

NASDAQ
HANG SENG

25,893.03 776.49(3.09%)